Home   >  
Apoptosis Pathway
  >  
Bcl2

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Bcl2

Chemical Structure Cat. No. Product Name CAS No.
Pyridoclax Chemical Structure
BCP23863 Pyridoclax 1651890-44-6
Pyridoclax is a potential Mcl-1 inhibitor.
AVN-944 Chemical Structure
BCP23877 AVN-944 297730-17-7
AVN944 is a biotech drug that demonstrated a statistically meaningful impact on IMPDH and other proteins that are critical to activities in cancer cells, including nucleotide biosynthesis, energy and metabolism, DNA replication, apoptosis and cell cycle control. AVN944 has been associated with cancer cell death in clinical trials. It is being investigated for the treatment of patients with advanced hematologic malignancies.
(R)-MIK665 Chemical Structure
BCP47788 (R)-MIK665 1799831-02-9
(R)-MIK665 is the less active enantiomer of MIK665. MIK665 is a special Mcl-1 inhibitor with an IC50 of 1.81 nM.
Lisaftoclax Chemical Structure
BCP47569 Lisaftoclax 2180923-05-9
Lisaftoclax exhibits IC50 values of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4;11 cells and Bcl-xl dependent Molm13 cells.
SMBA1 Chemical Structure
BCP45276 SMBA1 906440-37-7
SMBA1 is a selective acrivator of Bax, a central death regulator. It acts by potently suppressing lung tumour growth via apoptosis.
BI-3802 Chemical Structure
BCP41514 BI-3802 2166387-65-9 
BI-3802 is a BCL6 inhibitor, with an IC50 of ≤3 nM. BI-3802 shows an IC50 of 43 nM for the cellular BCL6.
Mcl1-IN-2 Chemical Structure
BCP40301 Mcl1-IN-2 292057-76-2
Mcl1-IN-2, a hydroxyquinoline derivative, is an Mcl-1 inhibitor.
APG-2575 Chemical Structure
BCP40069 APG-2575 APG2575
APG-2575 is a novel, orally administered small-molecule Bcl-2‒selective inhibitor.
BDA-366 Chemical Structure
BCP39785 BDA-366 1909226-00-1
BDA-366 is a small-molecule Bcl2-BH4 domain antagonist, BDA-366, that binds BH4 with high affinity and selectivity.
S55746 Chemical Structure
BCP39114 S55746 1448584-12-0
S55746 is an orally available BCL-2 specific inhibitor (Ki = 1.3 nM), displaying 70 to 400-fold selectivity for BCL-2 over BCL-XL.
123下一页末页共 55 条记录 1 / 6 页 
0086-13720134139